CRP and type 2 diabetes mellitus: A meta-analysis of 40 randomized controlled trials with a median follow-up of 6 months showed that treatment with GLP-1RA was associated with significant improvement of biomarkers of inflammation and oxidative stress, such as C-reactive protein, TNF-alpha, malondialdehyde, and adiponectin in overweight type 2 diabetic patients with a mean HbA1c of 55.6 mmol/mol (7.26%), compared to placebo or conventional glucose-lowering drugs [5].